Home About Us Industry Report Store Resources Contact us

Bile Duct Cancer Market Research Report 2024

Bile Duct Cancer Market Global Industry Analysis And Forecast (2024- 2032) By Product Type (Capecitabine, 5-fluorouracil (5-FU), Oxaliplatin, Gemcitabine, Cisplatin), Disease Indication (Extrahepatic Bile Duct Cancer, Intrahepatic Bile Duct Cancer), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Photodynamic Therapy), End-User(Hospitals, Cancer Research Centers, Specialty Clinics, Home healthcare, ambulatory surgical centers) And Region

0/5
( 0 votes )

Report ID: 276

Categories: Healthcare

Format :

Summary TOC Segmentation Methodology

Global Bile Duct Cancer Market Synopsis

The Bile Duct Cancer market was worth USD 3.6 Billion in 2023. As such, the forecast is that the market is expected to reach USD 7.26 Billion by 2032 with a CAGR of 8.1% over the period from 2024 to 2032.

Bile duct cancer, also known as cholangiocarcinoma, is a type of cancer that forms in the bile ducts, which are the tubes that carry bile from the liver to the gallbladder and small intestine. Bile duct cancer is a rare disease in which malignant (cancer) cells form in the bile ducts. Bile duct cancer is also called cholangiocarcinoma.

  • The small ducts come together to form the right and left hepatic ducts, which lead out of the liver. The two ducts join outside the liver and form the common hepatic duct. The cystic duct connects the gallbladder to the common hepatic duct. Bile from the liver passes through the hepatic ducts, common hepatic duct, and cystic duct and is stored in the gallbladder. When food is being digested, bile stored in the gallbladder is released and passes through the cystic duct to the common bile duct and into the small intestine.
  • Intrahepatic bile duct cancer type of cancer forms in the bile ducts inside the liver. Only a small number of bile duct cancers are intrahepatic. Intrahepatic bile duct cancers are also called intrahepatic cholangiocarcinomas.
  • Extrahepatic bile duct cancer type of cancer forms in the bile ducts outside the liver. The two types of extrahepatic bile duct cancer are perihilar bile duct cancer and distal bile duct cancer. The perihilar bile duct cancer type of cancer is found in the area where the right and left bile ducts exit the liver and join to form the common hepatic duct. Perihilar bile duct cancer is also called a Klatskin tumor or perihilar cholangiocarcinoma.
  • Distal bile duct cancer type of cancer is found in the area where the ducts from the liver and gallbladder join to form the common bile duct. The common bile duct passes through the pancreas and ends in the small intestine. Distal bile duct cancer is also called extrahepatic cholangiocarcinoma

Top Key Players

"Johnson & Johnson Private Limited (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), AbbVie Inc. (US), Novartis AG (Switzerland), Fresenius Kabi AG (Germany), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Intercept Pharmaceuticals (US), Kyowa Kirin Co., Ltd. (Japan), Delcath Systems, Inc. (US), Accord Healthcare (US), CONMED Corporation (US), Boston Scientific Corporation (US), Bayer AG (Germany), Bristol-Myers Squibb Company (US), Merck & Co., Inc. (US), and Other Active Players."

Global Bile Duct Cancer Market Trend Analysis

Increasing Incidence and Prevalence:

  • The rising incidence and prevalence of bile duct cancer, also known as cholangiocarcinoma, are critical factors driving the growth of the bile duct cancer market. This rare but aggressive cancer, originating in the bile ducts, has seen a noticeable increase globally. Factors such as aging populations, increased exposure to risk factors like liver fluke infections, chronic liver diseases, and certain genetic conditions contribute to this upward trend.
  • Early diagnosis remains challenging due to the asymptomatic nature of early-stage bile duct cancer, leading to late-stage discoveries and a higher demand for advanced treatments. The growing prevalence necessitates innovative therapeutic approaches, spurring investment in research and development. Pharmaceutical companies are increasingly focused on developing targeted therapies, immunotherapies, and personalized medicine to improve patient outcomes.
  • Additionally, improved diagnostic techniques and greater awareness among healthcare providers are contributing to more frequent and accurate diagnoses. This awareness fuels the market, as more patients seek treatment options, including surgeries, chemotherapy, and emerging therapies. Consequently, the escalating incidence and prevalence of bile duct cancer significantly influence market dynamics, driving the demand for advanced diagnostic tools and effective treatment modalities.

Development of non-invasive and cost-effective screening tools Creates an Opportunity for the Global Bile Duct Cancer Market

  • The bile duct cancer market presents significant development opportunities, particularly in the area of non-invasive and cost-effective screening tools. Bile duct cancer, or cholangiocarcinoma, often presents late with poor prognosis due to the lack of early symptoms and effective screening methods. Innovations in non-invasive screening can revolutionize early detection, thereby improving patient outcomes and survival rates.
  • Technological advancements such as liquid biopsies, which analyze biomarkers in blood samples, and advanced imaging techniques can provide early and accurate detection of bile duct cancer without the need for invasive procedures. These methods can detect circulating tumor DNA (ctDNA), proteins, and other cancer-specific markers, offering a less risky and more patient-friendly approach compared to traditional biopsies and endoscopic procedures.
  • Moreover, integrating artificial intelligence and machine learning algorithms into imaging and biomarker analysis can enhance the accuracy and efficiency of these screenings. The affordability and accessibility of such tools can significantly reduce healthcare costs and make screening more widely available, particularly in low-resource settings.

Global Bile Duct Cancer Market Segment Analysis:

Global Bile Duct Cancer Market is Segmented into Product Type, Disease Indication, Treatment Type, End User, and Region.

By Product Type, the Capecitabine segment is expected to dominate the market during the forecast period.

  • Capecitabine is anticipated to dominate the Bile Duct Cancer Market due to its significant therapeutic efficacy and versatility in treating this rare and aggressive cancer. Capecitabine, an oral chemotherapeutic agent, is converted into 5-fluorouracil (5-FU) in the body, selectively targeting cancer cells and disrupting their DNA synthesis. This targeted approach enhances its effectiveness while minimizing systemic toxicity.
  • One of the key advantages of Capecitabine is its oral administration, which offers patients greater convenience compared to intravenous chemotherapy, improving their quality of life. Additionally, its favorable safety profile and manageable side effects make it a preferred choice for both patients and healthcare providers.
  • Clinical studies have demonstrated Capecitabine's efficacy in treating bile duct cancer, either as a monotherapy or in combination with other chemotherapeutic agents and targeted therapies. Its ability to be integrated into combination therapies further enhances its therapeutic potential, addressing the complex nature of bile duct cancer.

By Disease Indication, the Extrahepatic Bile Duct Cancer segment held the largest share of 62.8% in 2023.

  • The Extrahepatic Bile Duct Cancer segment dominates the Bile Duct Cancer Market due to several key factors. This type of cancer, occurring outside the liver, is more commonly diagnosed compared to intrahepatic bile duct cancer, driving its prominence in the market. Enhanced diagnostic techniques and increased awareness have led to earlier detection, contributing to the segment's dominance.
  • Additionally, the availability of targeted therapies and advanced treatment options specifically for extrahepatic bile duct cancer has improved patient outcomes, fostering market growth. Pharmaceutical companies are increasingly focusing on developing drugs for this indication, further boosting the segment's market share.
  • The aging population and rising incidence of risk factors such as chronic liver diseases, obesity, and diabetes contribute to the growing prevalence of extrahepatic bile duct cancer. The high healthcare expenditure and investment in research and development for effective treatments also support the segment's leading position.

Global Bile Duct Cancer Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast Period

  • North America is expected to dominate the bile duct cancer market due to several key factors. Primarily, the region benefits from a well-established healthcare infrastructure, which facilitates advanced diagnostic and treatment options for bile duct cancer. The presence of leading pharmaceutical companies and extensive research and development activities contribute to the availability of innovative therapies.
  • Moreover, North America has a high prevalence of risk factors associated with bile duct cancer, such as obesity, chronic liver disease, and certain genetic conditions. This leads to a higher incidence rate, driving the demand for effective treatments. The region's robust healthcare expenditure ensures significant investment in cancer care, enhancing patient access to cutting-edge treatments
  • Additionally, North America's regulatory environment, particularly the FDA, accelerates the approval of new cancer therapies, ensuring the timely availability of novel treatments to patients. The region also has a high awareness of cancer screening and early detection, contributing to better outcomes and increased survival rates.

 Global Bile Duct Cancer Market Top Key Players:

  • Johnson & Johnson Private Limited (US)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd. (Jerusalem)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • AbbVie Inc. (US)
  • Novartis AG (Switzerland)
  • Fresenius Kabi AG (Germany)
  • Eli Lilly and Company (US)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Intercept Pharmaceuticals (US)
  • Kyowa Kirin Co., Ltd. (Japan)
  • Delcath Systems, Inc. (US)
  • Accord Healthcare (US)
  • CONMED Corporation (US)
  • Boston Scientific Corporation (US)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (US)
  • Merck & Co., Inc. (US), and Other Active Players.

Key Industry Developments:-

  • In February 2023, AstraZeneca, a global biopharmaceutical company, received approval from the Central Drugs Standard Control Organisation (CDSCO) to introduce Durvalumab for treating biliary tract cancer (BTC) in India. BTC encompasses a set of uncommon and aggressive gastrointestinal (GI) cancers originating from the cells of the bile ducts (cholangiocarcinoma), gallbladder, or ampulla of Vater (junction of the bile and pancreatic ducts with the small intestine).

Global Bile Duct Cancer Market

Base Year:

2023

Forecast Period:

2024- 2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 3.6 Bn.

Forecast Period 2024-32 CAGR:

8.1%

Market Size in  2032:

USD 7.26 Bn.

Segments Covered:

By Product Type

  • Capecitabine
  • 5-fluorouracil (5-FU)
  • Oxaliplatin
  • Gemcitabine
  • Cisplatin

By Disease Indication

  • Extrahepatic Bile Duct Cancer
  • Intrahepatic Bile Duct Cancer

By Treatment Type

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Immunotherapy
  • Photodynamic Therapy

By End-User

  • Hospitals
  • Cancer Research Centers
  • Specialty Clinics
  • Home healthcare
  • Ambulatory Surgical Centers

By Region

  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Frequently Asked Questions

What would be the forecast period in the Global Bile Duct Cancer Market research report?

The forecast period in the Global Bile Duct Cancer Market research report is 2024- 2032.

Who are the key players in the Global Bile Duct Cancer Market?

Johnson & Johnson Private Limited (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), AbbVie Inc. (US), Novartis AG (Switzerland), Fresenius Kabi AG (Germany), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Intercept Pharmaceuticals (US), Kyowa Kirin Co., Ltd. (Japan), Delcath Systems, Inc. (US), Accord Healthcare (US), CONMED Corporation (US), Boston Scientific Corporation (US), Bayer AG (Germany), Bristol-Myers Squibb Company (US), Merck & Co., Inc. (US), and Other Active Players.

What are the segments of the Global Bile Duct Cancer Market?

The global Bile Duct Cancer Market is Segmented into Product Type, Disease Indication, Treatment Type, End User, and region. Product Type The market is categorized into Capecitabine, 5-fluorouracil (5-FU), Oxaliplatin, Gemcitabine, and Cisplatin. Disease Indication The market is categorized into Extrahepatic Bile Duct Cancer, and Intrahepatic Bile Duct Cancer. Treatment Type The market is categorized into Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, and Photodynamic Therapy. End-User The market is categorized into Hospitals, Cancer Research Centers, Specialty Clinics, Home healthcare, and ambulatory surgical centers. By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).

What is the Global Bile Duct Cancer Market?

Bile duct cancer, also known as cholangiocarcinoma, is a type of cancer that forms in the bile ducts, which are the tubes that carry bile from the liver to the gallbladder and small intestine. Bile duct cancer is a rare disease in which malignant (cancer) cells form in the bile ducts. Bile duct cancer is also called cholangiocarcinoma.

How big is the Global Bile Duct Cancer Market?

The Bile Duct Cancer market was worth USD 3.6 Billion in 2023. As such, the forecast is that the market is expected to reach USD 7.26 Billion by 2032 with a CAGR of 8.1% over the period from 2024 to 2032.

Select Licence Type

Single User

US$ 3200

Corporate User

US$ 4500

Excel Datapack

US$ 1500

Yearly Membership/Subscription

Connect with our sales team

Why Pristine Intelligence LLP

100%

Customer
Satisfaction

24x7+

Availability - we are always
there when you need us

200+

Fortune 50 Companies trust
Pristine Intelligence LLP

80%

of our reports are exclusive
and first in the industry

100%

more data
and analysis

1000+

reports published
till date